Nintedanib for treating idiopathic pulmonary fibrosis

  • Technology appraisal guidance
  • TA379
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre (SHTAC):

  • Cooper K, Kalita N, Rose M, et al. Nintedanib for treating idiopathic pulmonary fibrosis: A Single Technology Appraisal, July 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Boehringer Ingelheim

II. Professional/expert and patient/carer groups:

  • Action for Pulmonary Fibrosis

  • British Thoracic Society

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

III. Other consultees:

  • Department of Health

  • NHS England

  • NHS Nottingham City CCG

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Roche Products

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on nintedanib by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the ACD.

  • Dr Toby Maher, Consultant Respiratory Physician, nominated by NHS England – clinical expert

  • Phillip Lloyd Mayers, Specialist Respiratory and ILD Pharmacist, nominated by United Kingdom Clinical Pharmacy Association – clinical expert

  • Michael Bray, Chair of trustees for Action for Pulmonary Fibrosis, nominated by Action for Pulmonary Fibrosis – patient expert

  • Peter Burns, Secretary of Papworth IPF patient support group, nominated by Pulmonary Fibrosis Trust – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy. They were also invited to comment on the ACD.

  • Boehringer Ingelheim

ISBN: 978-1-4731-1644-3